基于网络药理学探讨血府逐瘀汤治疗甲状腺功能减退症的作用机制
Discussion on the Mechanism of Xuefu Zhuyu Decoction in Treating Hypothyroidism Based on Network Pharmacology
DOI: 10.12677/TCM.2024.131021, PDF,   
作者: 张 强*, 蔡萧君#：黑龙江省中医药科学院，黑龙江 哈尔滨
关键词: 网络药理学；血府逐瘀汤；甲状腺功能减退症；Network Pharmacology； Xuefu Zhuyu Decoction； Hypothyroidism
摘要: 目的：基于网络药理学探讨血府逐瘀汤治疗甲状腺功能减退症的作用机制。方法：运用中医药系统药理学数据库与分析平台(TCMSP)、本草组鉴(HERB)平台筛选出血府逐瘀汤组成药物的活性成分，利用有机小分子生物活性数据库(PubChem)查找活性成分的化学结构，根据化学结构在SwissTargetPrediction数据库预测活性成分的潜在靶点。在Genecards数据库及Disgenet数据库中检索甲状腺功能减退症的相关靶点。利用韦恩图获得药物靶点及疾病靶点的交集靶点基因。利用STRING数据库对药物与疾病交集靶点进行蛋白质相互作用网络构建，获得血府逐瘀汤治疗甲状腺功能减退症的关键靶点。利用David数据库对交集靶点进行基因组百科全书(KEGG)信号通路与基因本体论(GO)功能富集分析。结果：得到药物有效成分208个，药物靶点1066个，甲状腺功能减退症靶点1386个，最终取交集靶点195个，KEGG信号通路20条。血府逐瘀汤治疗甲状腺功能减退症的关键靶点为STAT3、EP300、AKT1、MAPK1。关键的信号通路包括：肿瘤信号通路、糖尿病并发症中的AGE-RAGE信号通路等。结论：本研究初步揭示了血府逐瘀汤多成分、多靶点、多途径治疗甲状腺功能减退症的机制，为血府逐瘀汤的临床开发利用提供了依据。
Abstract: Objective: To explore the mechanism of Xuefu Zhuyu decoction in treating hypothyroidism based on network pharmacology. Methods: The active components of Xuefu Zhuyu Decoction were screened by TCM Pharmacology Database and Analysis Platform (TCMSP) and HERB Platform, and the chem-ical structure of the active components was found by PubChem, and the potential targets of the ac-tive components were predicted in SwissTargetPrediction database according to the chemical structure. Searching the related targets of hypothyroidism in Genecards database and Disgenet da-tabase, the intersection target genes of drug targets and disease targets were obtained by Wayne diagram. Protein interaction network was constructed for the intersection targets of drugs and dis-eases by using STRING database, and the key targets of Xuefuzhuyu decoction in treating hypothy-roidism were obtained. Using David database, the signal pathway of KEGG and the function enrich-ment of GO were analyzed. Results: 208 active ingredients, 1066 drug targets and 1386 hypothy-roidism targets were obtained. Finally, 195 intersecting targets and 20 KEGG signal pathways were selected. The key targets of Xuefu Zhuyu decoction in treating hypothyroidism are STAT3, EP300, AKT1 and MAPK1. Key signal pathways include: tumor signal pathway, AGE-RAGE signal pathway in diabetic complications, etc. Conclusion: This study initially revealed the mechanism of Xuefu Zhuyu Decoction in treating hypothyroidism with multi-components, multi-targets and multi-channels, which provided a basis for the clinical development and utilization of Xuefu Zhuyu Decoction.
文章引用：张强, 蔡萧君. 基于网络药理学探讨血府逐瘀汤治疗甲状腺功能减退症的作用机制[J]. 中医学, 2024, 13(1): 123-132. https://doi.org/10.12677/TCM.2024.131021

参考文献

[1] Garmendia, M.A., Santos, P.S., Guillén-Grima, F. and Galofré, J.C. (2014) The Incidence and Prevalence of Thyroid Dysfunction in Europe: A Meta-Analysis. The Journal of Clinical Endocrinology & Metabolism, 99, 923-931. [Google Scholar] [CrossRef] [PubMed]
[2] Li, Y., Teng, D., Ba, J., et al. (2020) Efficacy and Safety of Long-Term Universal Salt Iodization on Thyroid Disorders: Epidemiological Evidence from 31 Provinces of Mainland China. Thy-roid, 30, 568-579. [Google Scholar] [CrossRef] [PubMed]
[3] Kantor, E.D., Rehm, C.D., Haas, J.S., Chan, A.T. and Giovannucci, E.L. (2015) Trends in Prescription Drug Use among Adults in the United States from 1999-2012. JAMA, 314, 1818-1831. [Google Scholar] [CrossRef] [PubMed]
[4] ClinCalc Drug Stats Database (2021) Levothyroxine: Drug Usage Statistics, U.S., 2013-2019. https://clincalc.com/DrugStats/Drugs/Levothyroxine
[5] Brito, J.P., Ross, J.S., El Kawkgi, O.M., et al. (2021) Levo-thyroxine Use in the United States, 2008-2018. JAMA Internal Medicine, 181, 1402-1405. [Google Scholar] [CrossRef] [PubMed]
[6] 余桂枝, 喻远霞, 范建民, 张稳. 王行宽辨证治疗甲状腺功能减退症经验[J]. 中国中医药信息杂志, 2021, 28(3): 117-119. [Google Scholar] [CrossRef] 
[7] 赵鹏云, 郭俊杰. 郭俊杰治疗桥本甲状腺炎伴甲状腺功能减退症经验[J]. 湖南中医杂志, 2018, 34(11): 25-26. [Google Scholar] [CrossRef] 
[8] 王丽丹, 张广德. 魏子孝活用经方辨治甲状腺功能减退症经验[J]. 世界中西医结合杂志, 2021, 16(3): 446-449+453. [Google Scholar] [CrossRef] 
[9] 俞烨晨, 杨帆, 王旭. 浅析王旭教授治疗桥本甲状腺炎甲状腺功能减退临床经验[J]. 四川中医, 2021, 39(3): 3-6.
[10] 房璁璁, 陈如泉. 陈如泉教授治疗甲状腺功能减退症合并贫血经验[J]. 世界中医药, 2017, 12(4): 853-856.
[11] 任永丽, 任明, 牟蛟, 张曾譻. “心脑血脉宁”治疗甲状腺功能减退症的临床观察[J]. 天津中医药, 2017, 34(6): 373-376.
[12] 李秋莲, 刘海鹏, 王颜琦, 范源. 基于数据挖掘的近10年中医辨治甲状腺功能减退症用药规律探讨[J]. 云南中医学院学报, 2020, 43(6): 79-84. [Google Scholar] [CrossRef] 
[13] 贾锡莲. 甲状腺功能减退症的中医治疗与实验研究进展[J]. 医学综述, 2007, 13(9): 716-718.
[14] 徐锦平, 徐德凤. 徐德凤辨治甲状腺功能减退症经验[J]. 辽宁中医杂志, 2006, 33(2): 149-150. [Google Scholar] [CrossRef] 
[15] 徐蓉娟, 葛芳芳, 李红. 中医辨治甲状腺功能减退症[J]. 上海中医药大学学报, 2007, 21(6): 42-43. [Google Scholar] [CrossRef] 
[16] 李静, 高天舒. 高天舒教授治疗原发性甲状腺功能减退症经验介绍[J]. 新中医, 2007, 39(11): 8-9. [Google Scholar] [CrossRef] 
[17] 温志歌, 黄一珊, 赵林华. 补肾健脾法治疗肥胖合并甲状腺功能减退验案一例[J]. 环球中医药, 2023, 16(6): 1211-1214.
[18] 吴天强. 桥本甲状腺炎合并甲减的中医证型分布及相关因素分析[D]: [硕士学位论文]. 哈尔滨: 黑龙江中医药大学, 2023.[CrossRef] 
[19] 徐波. 中医药治疗桥本甲状腺炎的研究进展[J]. 中医研究, 2022, 35(10): 91-96.
[20] Lee, M., Shin, H., Park, M., Kim, A., Cha, S. and Lee, H. (2022) Systems Pharmacol-ogy Approaches in Herbal Medicine Research: A Brief Review. BMB Reports, 55, 417-428. [Google Scholar] [CrossRef] 
[21] O’Shea, J.J. and Plenge, R. (2012) JAK and STAT Signaling Molecules in Immunoregulation and Immune-Mediated Disease. Immunity, 36, 542-550. [Google Scholar] [CrossRef] [PubMed]
[22] Zhang, Q., Lenardo, M.J. and Baltimore, D. (2017) 30 Years of NF-κB: A Blossoming of Relevance to Human Pathobiology. Cell, 168, 37-57. [Google Scholar] [CrossRef] [PubMed]
[23] Li, J., Yin, Z., Huang, B., Xu, K. and Su, J. (2022) Stat3 Signaling Pathway: A Future Therapeutic Target for Bone-Related Diseases. Frontiers in Pharmacology, 13, Article ID: 897539. [Google Scholar] [CrossRef] [PubMed]
[24] Philips, R.L., Wang, Y., Cheon, H., et al. (2022) The JAK-STAT Pathway at 30: Much Learned, Much More to Do. Cell, 185, 3857-3876. [Google Scholar] [CrossRef] [PubMed]
[25] Kamyshna, I. and Kamyshnyi, A. (2022) Transcription Factors and Regulators Pathway-Focused Genes Expression Analysis in Patients with Different Forms of Thyroid Pathology. Cur-rent Pharmaceutical Biotechnology, 23, 1396-1404. [Google Scholar] [CrossRef] [PubMed]
[26] Xiu, L., Xing, Q., Mao, J., Sun, H., Teng, W. and Shan, Z. (2018) miRNA-125b-5p Suppresses Hypothyroidism Development by Targeting Signal Transducer and Acti-vator of Transcription 3. Medical Science Monitor, 24, 5041-5049. [Google Scholar] [CrossRef] 
[27] Durbin, A.D., Wang, T., Wimalasena, V.K., et al. (2022) EP300 Se-lectively Controls the Enhancer Landscape of MYCN-Amplified Neuroblastoma. Cancer Discovery, 12, 730-751. [Google Scholar] [CrossRef] 
[28] 康春嵋, 李山, 郭志玲. 基于调控PI3K-AKT通路探讨艾灸关元穴治疗甲状腺功能减退的作用机制[J]. 世界中西医结合杂志, 2021, 16(10): 1831-1835. [Google Scholar] [CrossRef] 
[29] Xu, Y., Cai, H., You, C., et al. (2022) Structural Insights into Ligand Binding and Activation of the Human Thyrotropin-Releasing Hormone Receptor. Cell Research, 32, 855-857. [Google Scholar] [CrossRef] [PubMed]
[30] Yao, Y., Chang, X., Wang, D., et al. (2018) Roles of ERK1/2 and PI3K/AKT Signaling Pathways in Mitochondria-Mediated Apoptosis in Testes of Hypothyroid Rats. Toxicological Research (Cambridge), 7, 1214-1224. [Google Scholar] [CrossRef] 
[31] 刘小娜. β1肾上腺素受体、PI3K/AKT通路在甲减大鼠心力衰竭形成中的作用研究[D]: [硕士学位论文]. 石家庄: 河北医科大学, 2017.
[32] Chen, X.J., Gong, X.H., Jie, J.P., et al. (2019) Receptor for Advanced Glycation End Products Reveals a Mechanism Regulating Thyroid Hormone Secretion through the SIRT1/Nrf2 Pathway. Journal of Cellular Biochemistry, 120, 4582-4598. [Google Scholar] [CrossRef] [PubMed]